By Julia Karow

Faced with limited revenue, upcoming debt payments, and a dwindling amount of cash, Helicos BioSciences' outlook for 2012 remains bleak, despite the firm's recent cost-cutting measures.

Earlier this week, Helicos reported $725,000 in third-quarter revenue and a $798,000 net loss for the quarter. As of Nov. 1, it had $1.6 million in total available resources, including $275,000 in cash and equivalents and $1.33 million from a bridge debt financing facility it secured last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

In Genome Biology this week: miRNAs linked to diffuse large B-cell lymphoma outcomes, database of bird genomes, and more.